In Vivo Regulation of the Vi Antigen in Salmonella and Induction of Immune Responses with an In Vivo -Inducible Promoter
- 1 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (6) , 2481-2488
- https://doi.org/10.1128/iai.01265-10
Abstract
Salmonella enterica serovar Typhi, the agent of typhoid fever in humans, expresses the surface Vi polysaccharide antigen that contributes to virulence. However, Vi expression can also be detrimental to some key steps of S. Typhi infectivity, for example, invasion, and Vi is the target of protective immune responses. We used a strain of S. Typhimurium carrying the whole Salmonella pathogenicity island 7 (SPI-7) to monitor in vivo Vi expression within phagocytic cells of mice at different times after systemic infection. We also tested whether it is possible to modulate Vi expression via the use of in vivo -inducible promoters and whether this would trigger anti-Vi antibodies through the use of Vi-expressing live bacteria. Our results show that Vi expression in the liver and spleen is downregulated with the progression of infection and that the Vi-negative population of bacteria becomes prevalent by day 4 postinfection. Furthermore, we showed that replacing the natural tviA promoter with the promoter of the SPI-2 gene ssaG resulted in sustained Vi expression in the tissues. Intravenous or oral infection of mice with a strain of S. Typhimurium expressing Vi under the control of the ssaG promoter triggered detectable levels of all IgG subclasses specific for Vi. Our work highlights that Vi is downregulated in vivo and provides proof of principle that it is possible to generate a live attenuated vaccine that induces Vi-specific antibodies after single oral administration.This publication has 45 references indexed in Scilit:
- A Rapid Change in Virulence Gene Expression during the Transition from the Intestinal Lumen into Tissue Promotes Systemic Dissemination of SalmonellaPLoS Pathogens, 2010
- Searching for the elusive typhoid diagnosticBMC Infectious Diseases, 2010
- Global Trends in Typhoid and Paratyphoid FeverClinical Infectious Diseases, 2010
- TheSalmonella entericaSerotype Typhi Vi Capsular Antigen Is Expressed after the Bacterium Enters the Ileal MucosaInfection and Immunity, 2010
- The TviA auxiliary protein renders the Salmonella enterica serotype Typhi RcsB regulon responsive to changes in osmolarityMolecular Microbiology, 2009
- Effect of immune serum and role of individual Fcγ receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophagesImmunology, 2006
- Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular PolysaccharideThe Journal of Infectious Diseases, 2004
- Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinantGene, 1995
- Lack of Immune Response to the Vi Component of a Vi-Positive Variant of the Salmonella typhi Live Oral Vaccine Strain Ty21a in Human StudiesThe Journal of Infectious Diseases, 1991
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987